Shape Memory Medical Raises $10M for Aortic Trials

Shape Memory Medical completed enrollment in its 180-patient AAA-SHAPE pivotal trial in July, but the financial clock kept running. The company's new $10M convertible note will support the follow-up, data collection, and second clinical program that determine whether a promising polymer becomes a credible aortic platform.

August Global Partners led the financing as a new investor. Taiwania Capital also joined as a new investor, while HEAL Venture Lab supported the transaction. Shape Memory Medical did not disclose the note's valuation, conversion terms, discount, maturity, or cap.

The announcement matters because clinical enrollment is only the visible edge of a medtech evidence program. Shape Memory Medical is now carrying a fully enrolled pivotal trial with five years of follow-up while advancing a first-in-human study in a different aortic condition. The capital gives the company more capacity to run both clocks; it does not move either clock faster.

What the $10M is financing

Shape Memory Medical develops endovascular embolization devices built around a low-density, porous shape-memory polymer. The material is delivered through a catheter in compressed form, expands after contact with blood, conforms to irregular anatomy, and is designed to promote organized thrombus formation while remaining radiolucent for follow-up imaging.

The company reports that its technology has been used in more than 3,500 patients and that its products have regulatory approvals in more than 40 countries. Those figures show a platform with commercial and clinical operating history, but they are company-reported and do not establish safety or effectiveness for the investigational U.S. aortic uses now being studied.

The $10M note follows a $38M Series C announced in March 2024. That earlier round supported the AAA-SHAPE pivotal trial, product research, and commercial expansion. The new financing arrives after AAA-SHAPE enrollment, shifting the emphasis from recruiting a cohort toward maintaining the evidence record that cohort is supposed to produce.

AAA-SHAPE enters the long follow-up period

The AAA-SHAPE pivotal trial randomized 180 patients at 48 centers across the United States, Europe, and New Zealand. Participants were assigned in a 2:1 ratio to receive endovascular aneurysm repair, or EVAR, with Shape Memory Medical's investigational IMPEDE-FX RapidFill device or standard EVAR alone. The company announced completed enrollment on July 8, 2026, and plans to follow participants for five years.

EVAR places a stent graft inside the aorta to redirect blood flow away from an abdominal aortic aneurysm. The operation can reduce pressure on the weakened vessel, but the aneurysm sac remains. AAA-SHAPE is testing whether filling the space around the graft with the polymer device can improve sac regression and other outcomes compared with EVAR alone.

The trial's endpoints keep the story grounded. They include short-term freedom from specified major adverse events and the proportion of patients achieving at least a 10% reduction in aneurysm-sac volume without an AAA-related intervention through one year. Enrollment completion proves that the company and its clinical partners assembled the study population. It does not prove the device works, and it does not remove the operational risk of retaining patients, protecting data quality, and interpreting results over time.

FLAGSHIP starts a different evidence clock

Shape Memory Medical is also advancing FLAGSHIP, a prospective, single-arm, first-in-human feasibility study in aortic dissection. A dissection occurs when a tear in the aortic wall creates a secondary channel, or false lumen. Persistent blood flow through that channel can contribute to further enlargement, rupture, and other serious complications.

FLAGSHIP plans to enroll up to 30 patients and follow them for two years while evaluating the safety and preliminary efficacy of Shape Memory Medical's investigational False Lumen Embolization System. The purpose-built device comes in larger configurations than the company's commercial plugs; the largest disclosed model delivers roughly 76 times the volume of the company's largest commercially available plug.

That makes FLAGSHIP more than a second trial on the same product. It tests whether the polymer platform can move into a larger and more complex anatomical problem without losing the properties that make it interesting: catheter delivery, volumetric expansion, conformability, clot formation, and imaging visibility.

The investor signal and the clinical obligation

August Global Partners is a Singapore-based healthcare and advanced-manufacturing investor with an Asia-oriented network. Taiwania Capital invests across technology and biotech markets in Taiwan, the United States, Japan, Southeast Asia, and Central and Eastern Europe. AGP partner Davian Sim said the data ahead will define the company and linked the investment to both the clinical inflection point and potential Asia-Pacific expansion.

That rationale is useful because it explains what the syndicate is underwriting without pretending the answer is already known. Shape Memory Medical has an established embolization platform, a fully enrolled pivotal trial, and an adjacent first-in-human program. It also has years of clinical work ahead, undisclosed note economics, and no announced outcome from either current aortic study.

For operators, the practical lesson is less cinematic than the funding headline. Clinical credibility is built after the milestone, when a company keeps patients engaged, investigators aligned, data complete, and claims inside the evidence. The $10M note finances that discipline. Whether the platform earns broader adoption will be decided by the record the company produces with it.